Tirzepatide
Dual GIP/GLP-1 receptor agonist supported by large randomized trials and licensed in the UK for specific medical indications.
Mechanism & research rationale
Tirzepatide is a peptide agonist at GIP and GLP-1 receptors. Its pharmacology influences glucose-dependent insulin secretion, appetite/energy intake and metabolic regulation.
Human evidence
SURMOUNT-1 was a large phase 3 randomized trial in 2,539 adults with obesity or overweight without diabetes and demonstrated clinically substantial weight reduction over 72 weeks versus placebo. Tirzepatide also has extensive type 2 diabetes trial data. NICE guidance recognizes tirzepatide (Mounjaro) for managing overweight/obesity and type 2 diabetes in defined NHS populations.
Preclinical / translational evidence
Preclinical receptor pharmacology helped establish the rationale for dual GIP/GLP-1 agonism, but the compound now has extensive human clinical evidence and regulatory review.
Key limitations
- Evidence for licensed tirzepatide does not establish quality, safety or equivalence of an unlicensed research preparation.
- Clinical benefits and risks come from controlled pharmaceutical-grade products used under regulated conditions.
- The research library does not provide treatment or prescribing guidance.